A Dallas-based biotech company called Colossal Biosciences says it has produced “de-extinct” dire wolf pups using ...

CRISPR Therapeutics (NASDAQ:CRSP) has had a rough stretch lately. Shares have dropped 5% over the past week and are down 8% year-to-date, trading around $49.37 as of Tuesday morning. Piper Sandler, ...

Tools like CRISPR-Cas9 are creating new opportunities for innovation in St. Louis, as well as risks around IP protection and regulation.

Extremophiles may well be tiny, but they are making a huge contribution to the health of our planet and our lives. A new review of these microorganisms, published in the journal Frontiers in ...

Animal Genetics Market OverviewThe Animal Genetics Market is anticipated to grow at a CAGR of 6–7% between 2023 and 2028. This upward trajectory is driven by several influential factors, including the ...

The road to deploying the next flagship supercomputer at the National Energy Research Scientific Computing Center (NERSC) reached an important ...

We’re going to look back at some of the most talked-about 2018 inventions that actually made a difference, beyond just the ...

Genome and epigenome editors—including CRISPR nucleases, base editors, prime editors, and emerging RNA/epitranscriptomic editors—are advancing rapidly, but ...

Researchers at Case Western Reserve University found evidence that gut bacteria may contribute to brain damage in Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). Their study ...

Bank of America Securities analyst Alec Stranahan reiterated a Buy rating on Immatics today and set a price target of $17.00. Stranahan covers the Healthcare sector, focusing on stocks such as Novavax ...